258 results on '"Panera, Nadia"'
Search Results
2. FRI-544 KLB depletion fosters stem-like properties and epithelialmesenchymal transition plasticity in HepG2 cells
3. Angiopoietin-2 levels correlates with disease activity in children with nonalcoholic fatty liver disease
4. Correction to: Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects
5. Changes in Total Homocysteine and Glutathione Levels After Laparoscopic Sleeve Gastrectomy in Children with Metabolic-Associated Fatty Liver Disease
6. Antioxidant activity of Hydroxytyrosol and Vitamin E reduces systemic inflammation in children with paediatric NAFLD
7. Cytokine expression patterns in hospitalized children with Bordetella pertussis, Rhinovirus or co-infection
8. Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects
9. Lipid-Induced Hepatocyte-Derived Extracellular Vesicles Regulate Hepatic Stellate Cells via MicroRNA Targeting Peroxisome Proliferator-Activated Receptor-γ
10. Lipid-induced hepatocyte-derived extracellular vesicles regulate hepatic stellate cell via microRNAs targeting PPAR-γ.
11. The G-Quadruplex/Helicase World as a Potential Antiviral Approach Against COVID-19
12. A review of the pathogenic and therapeutic role of nutrition in pediatric nonalcoholic fatty liver disease
13. b-Klotho deficiency in hepatic stellate cells (HSCs) prompts inflammation, oxidative stress and a pro-fibrotic phenotype
14. The Role of the GH/IGF1 Axis on the Development of MAFLD in Pediatric Patients with Obesity
15. High concentrations of H2O2 trigger hypertrophic cascade and phosphatase and tensin homologue (PTEN) glutathionylation in H9c2 cardiomyocytes
16. Genetics, epigenetics and transgenerational transmission of obesity in children
17. Combination Treatment with Hydroxytyrosol and Vitamin E Improves NAFLD-Related Fibrosis
18. Hydroxytyrosol Recovers SARS-CoV-2-PLpro-Dependent Impairment of Interferon Related Genes in Polarized Human Airway, Intestinal and Liver Epithelial Cells
19. The different modulation of KLB expression impacts on liver damage in NAFLD patients and in an in vitro model: a novel druggable target?
20. Higher Levels of Plasma Hyaluronic Acid and N-terminal Propeptide of Type III Procollagen Are Associated With Lower Kidney Function in Children With Non-alcoholic Fatty Liver Disease
21. Additional file 2 of Correction to: Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects
22. Additional file 1 of Correction to: Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects
23. Perturbation of specific transcripts in peripheral blood mononuclear cells in breast cancer: a case control pilot study
24. Additional file 3 of Correction to: Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects
25. Mirnome analysis reveals novel molecular determinants in the pathogenesis of diet-induced nonalcoholic fatty liver disease
26. Changes in Total Homocysteine and Glutathione Levels After Laparoscopic Sleeve Gastrectomy in Children with Metabolic-Associated Fatty Liver Disease
27. Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetics effects
28. Targeting FGF19 binding to its receptor system: A novel therapeutic approach for hepatocellular carcinoma
29. Angiopoietin-2 levels correlates with disease activity in children with nonalcoholic fatty liver disease
30. Association between type two diabetes and non-alcoholic fatty liver disease in youth
31. Additional file 7 of Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects
32. Additional file 6 of Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects
33. Additional file 10 of Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects
34. Additional file 2 of Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects
35. Additional file 9 of Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects
36. Additional file 3 of Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects
37. Additional file 5 of Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects
38. Blood cell gene expression profiles: A narrative review of biomarkers and effects of low-dose ionizing radiation exposure
39. Additional file 8 of Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects
40. Hepatocyte-derived extracellular vesicles released during lipotoxicity regulate hepatic stellate cell pheno-type via delivery of specific miRNAs and modulation of PPAR-γ expression: 25
41. Phosphodiesterase 4D Depletion/Inhibition Exerts Anti-Oncogenic Properties in Hepatocellular Carcinoma
42. Pediatric Non-Alcoholic Fatty Liver Disease is Affected by Genetic Variants Involved in Lifespan/Healthspan
43. The KLB rs17618244 gene variant is associated with fibrosing MAFLD by promoting hepatic stellate cell activation
44. WED-507 - b-Klotho deficiency in hepatic stellate cells (HSCs) prompts inflammation, oxidative stress and a pro-fibrotic phenotype
45. Commentary: FGF21 Holds Promises for Treating Obesity-related Insulin Resistance and Hepatosteatosis
46. Retinoids Counteract Insulin Resistance And Liver Steatosis: Whatʼs the Potential Mechanism?
47. From pregnant women to infants: Non-alcoholic fatty liver disease is a poor inheritance
48. HDL cholesterol protects from liver injury in mice with intestinal specific LXRα activation
49. The pharmacological treatment of nonalcoholic fatty liver disease in children
50. Noninvasive diagnostic tools for pediatric NAFLD: where are we now?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.